Biotechnology company Trevena, Inc. (NASDAQ:TRVN) discovers and develops therapeutics to target G protein coupled receptors, or GPCRs.
Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update: Back on November 10th 2014 we predicted a spring 2015 high of 2181 …